Details for Patent: RE49647

« Back to Dashboard

Which drugs does patent RE49647 protect, and when does it expire?

Patent RE49647 protects ZENBEXUS and is included in one NDA.

This patent has thirty-seven patent family members in thirty-four countries.

Summary for Patent: RE49647

Title:	Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Abstract:	Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
Inventor(s):	Darshan Parikh, Anil Menon
Assignee:	Celgene Corp
Application Number:	US17/030,272
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent RE49647

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	RE49647		Y
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	RE49647		Y

International Family Members for US Patent RE49647

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	100663
Australia	2014332171
Brazil	112016007729
Canada	2921436
Chile	2016000816
China	105899196